Skip to content

Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations

GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02020876
Acronym
DECIDE
Enrollment
21
Registered
2013-12-25
Start date
2012-08-31
Completion date
2013-12-31
Last updated
2013-12-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

This clinical utility study pilot is based on a review of real but de-identified and randomized patient cases and aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test. This is a pilot study and the primary intent is to help guide development and design of future clinical utility studies for Decipher

Detailed description

The primary and secondary objectives will be assessed in retrospectively selected prostate cancer patients treated with radical prostatectomy with one or more adverse pathological features (APFs)

Interventions

Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.

Sponsors

GenomeDx Biosciences Corp
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
Yes

Inclusion criteria

Criteria (Participant enrollment) Inclusion Criteria Study participants: 1. Practicing board-certified urologic surgeons 2. Performing at least 40 radical prostate surgeries annually

Exclusion criteria

Study Participants: (1) Did not meet the inclusion criteria Criteria (Case selection) Inclusion Criteria Case File: Patient cases eligible for this study were treated with radical prostatectomy and have one or more adverse pathological features present defined as: Pathological Gleason score \>= 8 or Gleason score 7 with primary pattern 4; Pathological stage T3A (= Extraprostatic extension) or T3B (=Seminal vesicle invasion); Positive surgical margins Gleason grade upgrade from biopsy to surgery

Design outcomes

Primary

MeasureTime frameDescription
Change in treatment recommendation1.5 yearsTo determine the extent to which the use of the Decipher test influences treatment recommendations by physicians post radical prostatectomy (RP). This decision impact study aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test.

Secondary

MeasureTime frameDescription
Urologist's perception regarding the utility of the Decipher1.5 years* Changes in Urologists expressed level of confidence in the treatment recommendation as measured by the response to item 4a in the eCRF survey. * Urologist's perception regarding the utility of the Decipher test as measured by the responses to question 4b and 38b and 38c in the eCRF survey. * Agreement in treatment recommendation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026